RxDoctor Payments Data

Baochan Nguyen, MD

Ophthalmology · Newport News, VANPI 1629212683

Payments from drug & device makers

$409in general payments, 2019–2025

Across 12 payments — averaging $34.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$183
  • Aerie Pharmaceuticals, Inc.$141
  • Sun Pharmaceutical Industries Inc.$35
  • Harrow Eye, LLC$32
  • Bausch & Lomb Americas Inc.$19

What the payments were for

  • Food & beverage$409100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$409 in reported general payments places this provider in the 30th percentile of 509 ophthalmology providers in Virginia.

See all ophthalmology providers in Virginia

Medicare billing

Part B allowed, 2024
$279,712
Medicare patients
1,106
Services billed
2,248

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine104$141,783
XiidraLifitegrast25$31,877
Cyclosporine43$28,386
LumiganBimatoprost24$17,334
Latanoprost596$5,807
Brimonidine Tartrate119$4,661
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat214$4,224
Travoprost27$2,889
Prednisolone Acetate68$2,583
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol19$2,049
Timolol Maleate81$1,790
Fluorometholone19$1,425
Tobramycin-DexamethasoneTobramycin/Dexamethasone21$641
Acyclovir14$429
Ketorolac Tromethamine11$352

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra$19$31,87725 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 509 ophthalmology providers in Virginia.

Other ophthalmology in Newport News

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →